Powered 500 · 2026POWEREDS. 051 of 500
Anktiva's 2024 FDA approval validated a 30-year immunotherapy thesis and built a publicly traded biotech complementing his prior $7B+ in pharma exits — while Soon-Shiong also runs the Los Angeles Times.
Patrick Soon-Shiong is the surgeon-turned-billionaire who founded ImmunityBio, whose immunotherapy Anktiva won FDA approval for high-risk bladder cancer in 2024 and continues to expand through 2025-26.
He earlier sold Abraxis to Celgene for $2.9 billion and APP Pharmaceuticals to Fresenius for $4.6 billion. He also owns the Los Angeles Times.
Interview · In Pipeline
Sponsored placement
An invitation, extended to Powered readers.
Drive the Continental GT S.
Request a test driveBentley T&Cs apply
